Search

News & Events
Outstanding mentor named Eureka prize finalistLeading infectious diseases researcher, Clinical Associate Professor Deborah Lehmann AO, has been named a finalist for the Australian Museum Eureka Prizes for her work training and mentoring a new generation of researchers.

News & Events
Vaccination reminder program to boost immunisation rates across AustraliaFamilies throughout the country will trial a new text message vaccination reminder program designed to safeguard kids against infectious diseases thanks to a generous funding boost from the Ramaciotti Foundation.

News & Events
Pneumococcal vaccine sees hospital admissions for deadly pneumonia slashed by halfThousands of children born in Papua New Guinea (PNG) no longer face a future cut short by severe pneumonia, thanks to the introduction of pneumococcal vaccination as part of the country’s National Immunisation Program.

News & Events
Study finds Covid-19 severity reduced for childrenAn international study examining Covid-19 severity on hospitalised children and adolescents has found that as the virus became more infectious, intensive care admissions dropped across multiple age groups regardless of vaccination status.
The Kids Research Institute Australia's annual report highlights the accomplishments of our researchers, furthering our mission to secure a happier, healthier future for kids everywhere.

News & Events
Clinical trial recruiting babies for RSV and hMPV vaccine studyMEDIA ENQUIRIES Discover. Prevent. Cure. Mailing list Media contacts About The Kids Be Inspired Please direct general enquiries to our reception on (

Thanks to research, a six -second test can get the answers that could save a child’s life.

News & Events
Major grant empowers community voices to drive reduction in skin infectionsAboriginal community members throughout the Kimberley will take a lead role in driving healthy skin messages within their own communities thanks to a major funding boost to The Kids Research Institute Australia’s SToP Trial.
Research
Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country's first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season.
Research
“It’s all gone quiet…” MUSIC from COVID19Hannah Huong Christopher Moore Le Blyth OAM BSc (Hons) GradDipClinEpi PhD MA (Dev. Econ), MA (App. Stats), PhD (Econ) MBBS (Hons) DCH FRACP FRCPA PhD